Neurocrine Biosciences Inc
(NAS:NBIX)
$
139.51
-3.52 (-2.46%)
Market Cap: 14.12 Bil
Enterprise Value: 13.50 Bil
PE Ratio: 37.40
PB Ratio: 5.19
GF Score: 84/100 Neurocrine Biosciences Inc at Bank of America Global Research Healthcare Conference (Virtual) Transcript
May 11, 2021 / 03:00PM GMT
Release Date Price:
$91.45
(+0.23%)
Stephen Rogers Sloan
BofA Securities, Research Division - Research Analyst
All right. Thank you for joining us. I'm sorry about that. We had some technical difficulties on our end. I'm Stephen Sloan, I'm an associate on Tazeen Ahmad's small mid-cap biotech team. And it's my pleasure to be here with Neurocrine for the next, I guess, 20 minutes now.
On the call, we have Kevin Gorman, CEO; and Eric Benevich, Chief Commercial Officer. So thank you for joining us.
Kevin C. Gorman
Neurocrine Biosciences, Inc. - CEO & Director
Thanks, Stephen, and thanks to BAML for giving us this opportunity today.
Stephen Rogers Sloan
BofA Securities, Research Division - Research Analyst
No problem. It's our pleasure. So for those who aren't familiar with the company, could you just provide a brief overview before we get into some deeper questions?
Kevin C. Gorman
Neurocrine Biosciences, Inc. - CEO & Director
Sure. Before I start, I just want to remind everyone that we
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot